2018 ASCO Annual Meeting

Joseph A. Sparano, MD, Montefiore Medical Center, presenting LBA 1, TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score, during Plenary Press Briefing

Chicago, IL - 2018 ASCO Annual Meeting - Joseph A. Sparano, MD, Montefiore Medical Center, presenting LBA 1, TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node negative breast cancer and an intermediate prognosis 21-gene recurrence score, during Plenary Press Briefing at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Sunday June 3, 2018. Approximately 40,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 54th Annual Meeting, which is being held at McCormick Place. The ASCO Annual Meeting highlights the latest findings in all major areas of oncology, from basic to clinical and epidemiological studies. Photo by © ASCO/Zach Boyden-Holmes 2018 Technical Questions: todd@medmeetingimages.com; ASCO Contact: photos@asco.org